Maciej Wieczorek
2A Ogrodowa Street
Lomianki, MZ 05092, Poland
Lomianki, MZ 05092, Poland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 49 publications
Colloidal Light Scattering Distorts Fluorometric Quantification of mRNA in Lipid Nanoparticles.
Journal: Current issues in molecular biology
Published: July 07, 2026
Development of Bispecific Antibody Targeting Human IL-17A and IL-6.
Journal: Antibodies (Basel, Switzerland)
Published: January 23, 2026
Preclinical evaluation of CPL423: a novel potent small-molecule inhibitor of TAM family and FLT3 kinase for cancer therapy.
Journal: Frontiers in pharmacology
Published: December 15, 2025
PDE10A Inhibition in Schizophrenia: A Randomised, Placebo-Controlled Phase 2 Study of Alofropodect (CPL'36) in Patients Experiencing Acute Schizophrenia.
Journal: CNS drugs
Published: November 28, 2025
Identification of pyrrolo[2,3-d]pyrimidine-based dual MERTK and FLT3 inhibitor: Hit-to-lead, machine learning, modeling, synthesis, and biological evaluation.
Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
Published: October 31, 2025
Engineered fibroblast growth factor 1 variants uncouple glucose-lowering effects from mitogenic activity with therapeutic potential for type 2 diabetes.
Journal: Molecular biomedicine
Published: July 20, 2025
Factors Influencing the Dispersibility of Glycopyrronium Bromide and Indacaterol Maleate - Combined In Vitro and In Silico Study.
Journal: AAPS PharmSciTech
Published: April 10, 2025
First-in-human study of CPL'116 - a dual JAK/ROCK inhibitor - in healthy subjects.
Journal: Frontiers in pharmacology
Published: February 26, 2025
Dual JAK and ROCK inhibition with CPL'116 in patients with rheumatoid arthritis with inadequate response to methotrexate: a randomised, double-blind, placebo-controlled, phase 2 trial.
Journal: The Lancet. Rheumatology
Published: November 28, 2024
Development of the telescoped flow Pd-catalyzed aerobic alcohol oxidation/reductive amination sequence in the synthesis of new phosphatidylinositide 3-kinase inhibitor (CPL302415).
Journal: RSC advances
Published: July 08, 2024
Development of a Formulation and In Vitro Evaluation of a Pulmonary Drug Delivery System for a Novel Janus Kinase (JAK) Inhibitor, CPL409116.
Journal: Pharmaceutics
Published: June 14, 2024
Last Updated: 09/26/2026